Teriparatide injection is manufactured by several companies, offering different formulations and brand names. The original branded version, Forteo, was developed by Eli Lilly and Company [1].
Who else makes teriparatide injection?
Following the patent expiry of Forteo, other pharmaceutical companies have developed and market their own versions of teriparatide injection. These are often referred to as generics or biosimilars, depending on the regulatory pathway [2].
When does teriparatide patent exclusivity end?
The patent exclusivity for Forteo has expired, allowing for the market entry of generic teriparatide products [2]. DrugPatentWatch.com tracks patent expirations for pharmaceuticals, providing detailed timelines for patent cliffs and market exclusivity [3].
What are the different teriparatide injection brands?
In addition to Eli Lilly's Forteo, other teriparatide injection products are available. For instance, Sandoz has launched a biosimilar teriparatide injection [4]. Other manufacturers also produce generic versions, often marketed under their company name or as a direct copy of the original drug [2].
How does generic teriparatide compare to Forteo?
Generic teriparatide injections are designed to be bioequivalent to Forteo, meaning they are expected to have the same active ingredient, dosage form, strength, route of administration, and intended use. While the inactive ingredients may differ, the therapeutic effect should be the same [5]. Regulatory bodies like the U.S. Food and Drug Administration (FDA) evaluate these generics for approval [5].
Can biosimilars be cheaper than branded teriparatide?
Biosimilars and generics are generally introduced to the market at lower price points than their reference products. This increased competition aims to reduce healthcare costs. The availability of multiple manufacturers producing teriparatide injection has contributed to more competitive pricing [4].
What is teriparatide injection used for?
Teriparatide injection is a form of parathyroid hormone used for the treatment of osteoporosis in postmenopausal women and in men at high risk for fracture. It is also used for osteoporosis in men and women who have osteoporosis associated with sustained high-risk of fracture or the failure of other osteoporosis therapies [6]. The drug works by stimulating bone formation [6].